These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Biologic therapies for the treatment of asthma. Wagelie-Steffen AL; Kavanaugh AF; Wasserman SI Clin Chest Med; 2006 Mar; 27(1):133-47, vii. PubMed ID: 16543058 [TBL] [Abstract][Full Text] [Related]
3. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Nowak D Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266 [TBL] [Abstract][Full Text] [Related]
4. New treatments for asthma: current and future aspects. Hansel TT Curr Opin Pulm Med; 2001 Apr; 7 Suppl 1():S3-6. PubMed ID: 11385813 [TBL] [Abstract][Full Text] [Related]
5. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Sullivan SD; Turk F Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184 [TBL] [Abstract][Full Text] [Related]
7. Biologic immune modifiers: Trials and tribulations--are we there yet? Ballow M J Allergy Clin Immunol; 2006 Dec; 118(6):1209-15; quiz 1216-7. PubMed ID: 17157649 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756 [TBL] [Abstract][Full Text] [Related]
9. Anti-immunoglobulin E therapy with omalizumab for asthma. Hendeles L; Sorkness CA Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897 [TBL] [Abstract][Full Text] [Related]
10. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Holgate ST; Djukanović R; Casale T; Bousquet J Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747 [TBL] [Abstract][Full Text] [Related]
11. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714 [TBL] [Abstract][Full Text] [Related]
12. Omalizumab as add-on therapy to inhaled steroids for asthma. Hadj Tahar A Issues Emerg Health Technol; 2004 Jun; (58):1-4. PubMed ID: 15455487 [TBL] [Abstract][Full Text] [Related]
13. [Omalizumab, an anti-IgE monoclonal antibody to treat severe asthma]. Michils A; Sternon J J Pharm Belg; 2006; 61(3):83-7. PubMed ID: 17058881 [TBL] [Abstract][Full Text] [Related]
14. [Omalizumab, an anti-IgE monoclonal antibody to treat severe asthma]. Michils A; Sternon J Rev Med Brux; 2006; 27(3):167-72. PubMed ID: 16894955 [TBL] [Abstract][Full Text] [Related]
15. Omalizumab: efficacy in allergic disease. Spector S Panminerva Med; 2004 Jun; 46(2):141-8. PubMed ID: 15507883 [TBL] [Abstract][Full Text] [Related]
16. Newer therapies for asthma: a focus on anti-IgE. Babu KS; Holgate ST Indian J Chest Dis Allied Sci; 2002; 44(2):107-15. PubMed ID: 12026249 [TBL] [Abstract][Full Text] [Related]
17. Anti-IgE and other antibody targets in asthma. Singh J; Kraft M Handb Exp Pharmacol; 2008; (181):257-88. PubMed ID: 18071950 [TBL] [Abstract][Full Text] [Related]
18. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. Busse WW; Massanari M; Kianifard F; Geba GP Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616 [TBL] [Abstract][Full Text] [Related]
19. Newer therapeutic approaches to the vasculitides: biologic agents. Samuels J; Spiera R Rheum Dis Clin North Am; 2006 Feb; 32(1):187-200, xi. PubMed ID: 16504830 [TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin E blockade in the treatment of asthma. Kuhn R Pharmacotherapy; 2007 Oct; 27(10):1412-24. PubMed ID: 17896896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]